Search Results

There are 30616 results for: content related to: Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization

  1. You have free access to this content
    Cost effectiveness of gene expression profiling for early stage breast cancer

    Cancer

    Volume 118, Issue 20, 15 October 2012, Pages: 5163–5170, Mo Yang, Suja Rajan and Amalia M. Issa

    Version of Record online : 22 FEB 2012, DOI: 10.1002/cncr.27443

  2. Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives

    Psycho-Oncology

    Volume 22, Issue 9, September 2013, Pages: 2110–2116, Elizabeth Spellman, Nadiyah Sulayman, Susan Eggly, Beth N. Peshkin, Claudine Isaacs, Marc D. Schwartz and Suzanne C. O'Neill

    Version of Record online : 28 FEB 2013, DOI: 10.1002/pon.3264

  3. You have free access to this content
    Researchers find discordance between standard human epidermal growth factor receptor 2 (HER2) testing and HER2 status reported on Oncotype DX

    CA: A Cancer Journal for Clinicians

    Volume 62, Issue 2, March/April 2012, Pages: 71–72, Mary Kay Barton

    Version of Record online : 18 JAN 2012, DOI: 10.3322/caac.21133

  4. Impact of Oncotype DX on Treatment Decisions in ER-Positive, Node-Negative Breast Cancer with Histologic Correlation

    The Breast Journal

    Volume 19, Issue 3, May/June 2013, Pages: 269–275, Julianne R. Biroschak, Gordon F. Schwartz, Juan P. Palazzo, Adam D. Toll, Kristin L. Brill, Rebecca J. Jaslow and Sun Yong Lee

    Version of Record online : 24 APR 2013, DOI: 10.1111/tbj.12099

  5. Impact of Oncotype DX testing on adjuvant treatment decisions in patients with early breast cancer: A single-center study in the United Arab Emirates

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue 4, December 2014, Pages: 354–360, Hassan Jaafar, Mohamed Al Bashir, Ali Taher, Khaled Qawasmeh and Mohammed Jaloudi

    Version of Record online : 21 SEP 2014, DOI: 10.1111/ajco.12259

  6. Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?

    The Breast Journal

    Volume 21, Issue 5, September/October 2015, Pages: 514–519, Niamh Conlon, Dara S. Ross, Jane Howard, Jeffrey P. Catalano, Maura N. Dickler and Lee K. Tan

    Version of Record online : 14 AUG 2015, DOI: 10.1111/tbj.12445

  7. You have free access to this content
    Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers

    Cancer

    Volume 116, Issue 22, 15 November 2010, Pages: 5161–5167, Catherine M. Kelly, Savitri Krishnamurthy, Giampaolo Bianchini, Jennifer K. Litton, Ana M. Gonzalez-Angulo, Gabriel N. Hortobagyi and Lajos Pusztai

    Version of Record online : 3 NOV 2010, DOI: 10.1002/cncr.25269

  8. ER and PR Immunohistochemistry and HER2 FISH versus Oncotype DX: Implications for Breast Cancer Treatment

    The Breast Journal

    Volume 20, Issue 1, January/February 2014, Pages: 37–45, MiHee M. Park, Joshua J. Ebel, Weiquiang Zhao and Debra L. Zynger

    Version of Record online : 22 NOV 2013, DOI: 10.1111/tbj.12223

  9. Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study

    The Oncologist

    Volume 20, Issue 8, August 2015, Pages: 873–879, Joseph Gligorov, Xavier B. Pivot, William Jacot, Hervé L. Naman, Dominique Spaeth, Jean-Louis Misset, Rémy Largillier, Jean-Loup Sautiere, Anne de Roquancourt, Christophe Pomel, Philippe Rouanet, Roman Rouzier, Frederique M. Penault-Llorca and for The Francilian Breast Intergroup

    Version of Record online : 25 JUN 2015, DOI: 10.1634/theoncologist.2014-0467

  10. Is Oncotype DX Recurrence Score (RS) of Prognostic Value Once HER2-Positive and. Low-ER Expression Patients are Removed?

    The Breast Journal

    Volume 19, Issue 4, July/August 2013, Pages: 357–364, Meghan Milburn, Martin Rosman, Charles Mylander and Lorraine Tafra

    Version of Record online : 23 MAY 2013, DOI: 10.1111/tbj.12126

    Corrected by:

    Erratum: Erratum

    Vol. 19, Issue 5, 568, Version of Record online: 17 SEP 2013

  11. You have free access to this content
    Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact

    BJU International

    Volume 114, Issue 3, September 2014, Pages: 320–322, John W. Davis

    Version of Record online : 14 JUL 2014, DOI: 10.1111/bju.12695

  12. The financial burden of using Oncotype Dx for patients with lymph node-negative and estrogen receptor-positive breast cancer in Australia

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue 1, March 2014, Pages: 94–95, Shinichiro Sakata and Michelle Cronk

    Version of Record online : 29 MAY 2013, DOI: 10.1111/ajco.12077

  13. You have free access to this content
    Cost effectiveness of gene expression profiling for early stage breast cancer

    Cancer

    Volume 118, Issue 24, 15 December 2012, Pages: 6298–6299, Shelby D. Reed and Gary H. Lyman

    Version of Record online : 6 JUN 2012, DOI: 10.1002/cncr.27665

  14. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer

    Asia-Pacific Journal of Clinical Oncology

    Aaron C. Tan, Bob T. Li, Kazi Nahar, Suzanne Danieletto, Eva S. Fong, Trevor Currer, Andrew Parasyn, Philip Middleton, Heidi Wong, Denis Smart, Josie J. Rutovitz, Philip McCloud, T. Michael Hughes and Gavin M. Marx

    Version of Record online : 29 SEP 2017, DOI: 10.1111/ajco.12779

  15. You have full text access to this OnlineOpen article
    Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays

    Journal of Surgical Oncology

    Volume 115, Issue 6, May 1, 2017, Pages: 647–662, David M. Hyams, Eric Schuur, Javier Angel Aristizabal, Juan Enrique Bargallo Rocha, Cesar Cabello, Roberto Elizalde, Laura García-Estévez, Henry L. Gomez, Artur Katz and Aníbal Nuñez De Pierro

    Version of Record online : 17 FEB 2017, DOI: 10.1002/jso.24561

  16. You have free access to this content
    RESEARCH POSTER ABSTRACTS

    Value in Health

    Volume 13, Issue 7, November 2010, Pages: A250–A480,

    Version of Record online : 11 OCT 2010, DOI: 10.1111/j.1524-4733.2010.00791_2.x

  17. Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay

    Journal of Magnetic Resonance Imaging

    Volume 42, Issue 5, November 2015, Pages: 1398–1406, Elizabeth J. Sutton, Jung Hun Oh, Brittany Z. Dashevsky, Harini Veeraraghavan, Aditya P. Apte, Sunitha B. Thakur, Joseph O. Deasy and Elizabeth A. Morris

    Version of Record online : 7 APR 2015, DOI: 10.1002/jmri.24890

  18. You have free access to this content
    Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study

    Cancer

    Volume 121, Issue 12, June 15, 2015, Pages: 1937–1948, Ines Vaz-Luis, Melissa E. Hughes, Angel M. Cronin, Hope S. Rugo, Stephen B. Edge, Beverly Moy, Richard L. Theriault, Michael J. Hassett, Eric P. Winer and Nancy U. Lin

    Version of Record online : 10 MAR 2015, DOI: 10.1002/cncr.29310

  19. You have free access to this content
    RESEARCH PODIUM ABSTRACTS

    Value in Health

    Volume 13, Issue 7, November 2010, Pages: A239–A250,

    Version of Record online : 11 OCT 2010, DOI: 10.1111/j.1524-4733.2010.00791_1.x

  20. The Effect of Oncotype DX Recurrence Score on Treatment Recommendations for Patients with Estrogen Receptor–Positive Early Stage Breast Cancer and Correlation with Estimation of Recurrence Risk by Breast Cancer Specialists

    The Oncologist

    Volume 16, Issue 11, November 2011, Pages: 1520–1526, Jennifer E. Joh, Nicole N. Esposito, John V. Kiluk, Christine Laronga, M. Catherine Lee, Loretta Loftus, Hatem Soliman, Judy C. Boughey, Carol Reynolds, Thomas J. Lawton, Peter I. Acs, Lucio Gordan and Geza Acs

    Version of Record online : 20 OCT 2011, DOI: 10.1634/theoncologist.2011-0045